Comparing pOrtable MRI and TRUS-Fusion Prostate Biopsy to Assess aCcuracy of Prostate Cancer Detection

Launched by IMPERIAL COLLEGE LONDON · Jun 11, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to detect prostate cancer by comparing two methods of taking biopsies—one using a portable MRI scanner and the other using a traditional method called TRUS-MRI fusion. Currently, the standard process involves an MRI followed by targeted biopsies, which can be complicated, time-consuming, and costly. The portable MRI technology aims to simplify this process by allowing doctors to perform biopsies in one visit, potentially reducing errors and improving the accuracy of cancer detection.

To participate in this trial, men aged 18 and older who have abnormal prostate-specific antigen (PSA) levels or specific types of lesions on their MRI may be eligible. Participants will undergo both biopsy methods, and the order in which they receive each method will be randomly assigned. This trial will help researchers understand if the portable MRI method is as effective as the traditional method for finding prostate cancer. It’s important to note that individuals with certain medical devices, like pacemakers, or those unable to give consent cannot participate.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or above (no upper limit)
• • Raised age specific PSA
• • LIKERT/PIRADS 3 or above lesion on prostate mpMRI who have been advised to undergo a prostate biopsy.
• Exclusion Criteria:
• • Patients who are unable to undergo a diagnostic standard of care MRI due to metallic implants, foreign body or devices.
• • Patients with a Cardiac pacemaker or Implantable cardioverter-defibrillator (ICD).
• • Contraindication to performing a biopsy guided by a transrectal ultrasound probe
• • Unable to give informed consent to the study